Placebo Improvement in Pharmacologic Treatment of Menopausal Hot Flashes: Time Course, Duration, and Predictors

被引:38
作者
Freeman, Ellen W. [1 ]
Ensrud, Kristine E. [2 ,3 ]
Larson, Joseph C. [4 ]
Guthrie, Katherine A. [4 ]
Carpenter, Janet S. [5 ]
Joffe, Hadine [6 ,7 ,8 ]
Newton, Katherine M. [9 ]
Sternfeld, Barbara [10 ]
LaCroix, Andrea Z. [11 ]
机构
[1] Univ Penn, Dept Obstet Gynecol & Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Vet Affairs Hlth Syst, Dept Med, Div Epidemiol & Community Hlth, Minneapolis, MN USA
[3] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
[4] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, MsFlash Data Coordinating Ctr, Seattle, WA 98104 USA
[5] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA
[6] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Harvard Univ, Sch Med, Dana Farber Inst, Dept Psychosocial, Boston, MA USA
[9] Grp Hlth Res Inst, Seattle, WA USA
[10] Kaiser Permanente No Calif, Div Res, Oakland, CA USA
[11] Univ Calif San Diego, Womens Hlth Ctr, La Jolla, CA 92093 USA
来源
PSYCHOSOMATIC MEDICINE | 2015年 / 77卷 / 02期
基金
美国国家卫生研究院;
关键词
placebo response; placebo improvement; hot flash treatment; menopause; RANDOMIZED CONTROLLED-TRIAL; VASOMOTOR SYMPTOMS; MIDLIFE WOMEN; DEPRESSION SEVERITY; CLINICAL-TRIALS; SMOKING; ANTIDEPRESSANTS; ASSOCIATION; METABOLISM; MANAGEMENT;
D O I
10.1097/PSY.0000000000000143
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objectives To characterize the time course, duration of improvement, and clinical predictors of placebo response in treatment of menopausal hot flashes. Methods Data were pooled from two trials conducted in the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health network, providing a combined placebo group (n = 247) and a combined active treatment group (n = 297). Participants recorded hot flash frequency in diaries twice daily during treatment (Weeks 0-8) and subsequent follow-up (Weeks 9-11). The primary outcome variable was clinically significant improvement, defined as a 50% or greater decrease in hot flash frequency from baseline and calculated for each week in the study. Subgroups were defined a priori using standard clinical definitions for significant improvement and partial improvement. Clinical and demographic characteristics of the participants were evaluated as predictors of improvement. Results Clinically significant improvement with placebo accrued each treatment week, with 33% significantly improved at Week 8. Of placebo responders who were improved at both Weeks 4 and 8, 77% remained clinically improved at Week 11 after treatment ended. Independent predictors of significant placebo improvement in the final multivariable model were African American race (odds ratio [OR] = 5.61, 95% confidence interval [CI] = 2.41-13.07, p < .001), current smokers (OR = 2.30, 95% CI = 1.05-5.06, p = .038), and hot flash severity in screening (OR = 1.45, 95% CI = 1.00-2.10, p = .047). Conclusions Clinically significant improvement with placebo accrued throughout treatment with a time course similar to improvement with active drug. A meaningful number of participants in the placebo group sustained a clinically significant response after stopping placebo pills. The results suggest that nonspecific effects are important components of treatment and warrant further studies to optimize their contributions in clinical care.
引用
收藏
页码:167 / 175
页数:9
相关论文
共 32 条
[1]   CLINICAL-FEATURES OF DEPRESSED-PATIENTS WHO DO AND DO NOT IMPROVE WITH PLACEBO [J].
BROWN, WA ;
JOHNSON, MF ;
CHEN, MG .
PSYCHIATRY RESEARCH, 1992, 41 (03) :203-214
[2]   Joint Effects of Smoking and Gene Variants Involved in Sex Steroid Metabolism on Hot Flashes in Late Reproductive-Age Women [J].
Butts, Samantha F. ;
Freeman, Ellen W. ;
Sammel, Mary D. ;
Queen, Kaila ;
Lin, Hui ;
Rebbeck, Timothy R. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (06) :E1032-E1042
[3]   Overt versus covert treatment for pain, anxiety, and Parkinson's disease [J].
Colloca, L ;
Lopiano, L ;
Lanotte, M ;
Benedetti, F .
LANCET NEUROLOGY, 2004, 3 (11) :679-684
[4]   Harnessing the placebo effect: the need for translational research [J].
Colloca, Luana ;
Miller, Franklin G. .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2011, 366 (1572) :1922-1930
[5]   HOPKINS SYMPTOM CHECKLIST (HSCL) - SELF-REPORT SYMPTOM INVENTORY [J].
DEROGATIS, LR ;
LIPMAN, RS ;
RICKELS, K ;
UHLENHUTH, EH ;
COVI, L .
BEHAVIORAL SCIENCE, 1974, 19 (01) :1-15
[6]   Antidepressant Drug Effects and Depression Severity A Patient-Level Meta-analysis [J].
Fournier, Jay C. ;
DeRubeis, Robert J. ;
Hollon, Steven D. ;
Dimidjian, Sona ;
Amsterdam, Jay D. ;
Shelton, Richard C. ;
Fawcett, Jan .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (01) :47-53
[7]  
Freeman EW, 2014, MENOPAUSE, V21, P924, DOI [10.1097/GME.0000000000000196, 10.1097/gme.0000000000000196]
[8]   Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women A Randomized Controlled Trial [J].
Freeman, Ellen W. ;
Guthrie, Katherine A. ;
Caan, Bette ;
Sternfeld, Barbara ;
Cohen, Lee S. ;
Joffe, Hadine ;
Carpenter, Janet S. ;
Anderson, Garnet L. ;
Larson, Joseph C. ;
Ensrud, Kristine E. ;
Reed, Susan D. ;
Newton, Katherine M. ;
Sherman, Sheryl ;
Sammel, Mary D. ;
LaCroix, Andrea Z. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (03) :267-274
[9]   Hot flashes in the late reproductive years: Risk factors for African American and Caucasian women [J].
Freeman, EW ;
Sammel, MD ;
Grisso, JA ;
Battistini, M ;
Garcia-Espagna, B ;
Hollander, L .
JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2001, 10 (01) :67-76
[10]   Cigarette smoking, estrogen levels, and hot flashes in midlife women [J].
Gallicchio, L ;
Miller, SR ;
Visvanathan, K ;
Lewis, LM ;
Babus, J ;
Zacur, H ;
Flaws, JA .
MATURITAS, 2006, 53 (02) :133-143